Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Insights from 2024 ASCO® GU Annual Meeting
D

ASCO® GU 2024 Insights: "HER2 and PD-L1 Immunohistochemistry Expression, and HER2 Genomic Alterations - Associations and Clinical Outcomes for Advanced Bladder Cancer"

By Insights from 2024 ASCO® GU Annual Meeting FEATURING David Aggen
By Insights from 2024 ASCO® GU Annual Meeting FEATURING David Aggen
91 views
February 20, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Genitourinary
06:55
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "HER2 and PD-L1 Immunohistochemistry Ex…

Feat. D. Aggen
08:56
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "MEDI5752 (Volrustomig) in the 1L Treatment…

Feat. M. Voss
24:28
OncoAlert

The Best of GU Radiation Oncology

Feat. S. McBride
46:48
University of Colorado Cancer Center

Theranostics and the Changing Face of Prostate Cancer

Feat. M. Morris
08:05
ASCO 2022 Conference Coverage

ASCO 2022: A Phase II Study of Gem + Cis Chemo in MIBC With Bladder …

Feat. G. Iyer
44
Memorial Sloan Kettering Cancer Center

Lecture Summary - Results of Phase II Clinical Trial of Cabozantinib…

Feat. C. Lee
07:31
Memorial Sloan Kettering Cancer Center

Results of Phase II Clinical Trial of Cabozantinib + Nivolumab for A…

Feat. C. Lee
06:49
ASCO Genitourinary Cancers Symposium

ASCO GU 2022 on Gem & Cis as Neoadjuvant Chemo in High-Grade UTU…

Feat. W. Yip
06:24
ecancer

ASCO 2021 Update on mCRPC: VISION Trial Data on Lutetium-177-PSMA-617

Feat. M. Morris
04:46
Memorial Sloan Kettering Cancer Center

2020 Update on mRCC: Lenvatinib + Pembro After CPIs: Is There a Bene…

Feat. C. Lee